IRVINE, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that President and Chief Executive Officer Mark McDonough will present a company overview at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015, at 9:35 a.m. Eastern time (6:35 a.m. Pacific time). The conference is being held at the St. Regis Hotel in New York City.
A live webcast of the presentation will be available on the company's website at http://investor.combimatrix.com/events.cfm and will be archived for 30 days.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in prenatal diagnostics, miscarriage analysis for recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
CONTACT: Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 email@example.com Russo Partners LLC David Schull or Lena Evans (212) 845-4271 firstname.lastname@example.org email@example.com